Plus therapeutics reports second quarter 2024 financial results and recent business highlights

Presented positive interim respect-lm phase 1 data for rhenium ( 186 re) obisbemeda for leptomeningeal metastases presented positive topline clinical trial results for cnside diagnostic in the foresee trial management to host conference call august 14, 2024 at 5:00 p.m. et austin, texas, aug. 14, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced financial results for the second quarter ended june 30, 2024, and provided an overview of recent and upcoming business highlights.
PSTV Ratings Summary
PSTV Quant Ranking